Turalio cost?

Turalio (melphalan flufenamide) – approximate cost overview

Key points

1. High Cost – Turalio was one of the more expensive oncology drugs on the market. The list price per vial was often cited in the $5–$7 k range, leading to multi‑hundred‑thousand‑dollar treatment cycles for many patients.

2. Insurance & Copay – Because it was classified as a specialty drug, most commercial and Medicare Part D plans negotiated a tiered structure. Patients usually paid a copayment or coinsurance ranging from a few hundred to several thousand dollars per cycle, depending on formulary placement.

3. Availability – The FDA withdrew Turalio in 2022 after a study showed it did not improve survival in multiple myeloma and was associated with significant toxicity. As of now, the drug is not marketed in the United States, and new prescriptions are no longer being written. Therefore, the price figures above are historical and refer to the drug’s cost while it was still available.

4. Cost‑sharing & Assistance – Before withdrawal, manufacturers offered assistance programs for uninsured or under‑insured patients. If the drug were still available, similar programs might exist. For current coverage or assistance options, consult your pharmacist or the manufacturer’s patient support team.

5. Alternative Therapies – If you’re exploring treatment options for multiple myeloma or another indication, discuss current, approved alternatives with your oncologist. Newer agents (e.g., belantamab mafodotin, selinexor) may have different cost structures.

Quick FAQ

Bottom line: When Turalio was on the market, a single vial cost several thousand dollars, and a typical treatment cycle ran into the $80 k–$120 k range. Insurance usually covered most of that, leaving patients with a copay of a few thousand dollars. The drug is now off the market, so current cost considerations are largely academic unless you’re reviewing historical data or studying drug pricing trends.